Better Health for All

Sinovac Biotech's core business focuses on developing, manufacturing, and commercializing vaccines, directly contributing to improved public health. The company's product portfolio includes vaccines against various infectious diseases, including COVID-19 (CoronaVac). A BMJ study (

) investigated the effectiveness of CoronaVac against symptomatic COVID-19 in adults aged ≥70 years in São Paulo, Brazil, during a gamma variant-associated epidemic. The study found that adjusted vaccine effectiveness against symptomatic COVID-19 was 24.7% at 0-13 days and 46.8% at ≥14 days after the second dose. Effectiveness against hospital admissions was 55.5% and against deaths was 61.2% at ≥14 days after the second dose. However, the study also noted that effectiveness decreased with increasing age. The company's focus on vaccines for diseases prevalent in China and developing countries suggests a commitment to addressing health disparities. Given the limited evidence, a score of 10 is appropriate.

Fair Money & Economic Opportunity

Sinovac Biotech Ltd. is a biopharmaceutical company focused on the research, development, manufacturing, and commercialization of vaccines.

The provided articles do not contain any evidence that the company engages in activities related to lending, insuring, moving, or storing money, nor do they detail any financial products or services offered to consumers. Therefore, there is no relevant information to score against the KPIs for 'Fair Money & Economic Opportunity', which are designed for financial institutions.

Fair Pay & Worker Respect

In 2022, Sinovac reported zero injuries per million man-hours, zero major safety accidents, and zero staff suffering occupational diseases.

This translates to a Total Recordable Incident Rate (TRIR) of 0, which falls into the tier for TRIR <1.0. The company also reported a 100% employment contract signing rate and 100% social insurance coverage for its workforce in 2022, indicating that all employees are on secure contracts with full benefits. No specific regulatory actions, violations, fines, or compliance issues were mentioned in the 2022 Responsibility Report, aligning with a score of 0 for no public record of breaches.

Honest & Fair Business

A formal whistle-blower policy exists, adopted in April 2006, with a designated Compliance Officer and contact information.

The Audit Committee Charter, last amended in May 2019, outlines procedures for confidential and anonymous employee submissions of concerns regarding accounting, internal controls, and auditing matters. The company's anti-corruption policy, adopted in April 2006, explicitly prohibits bribery, kickbacks, and secret commissions. However, in 2015, Sinovac Biotech's CEO allegedly bribed a Chinese Food and Drug Administration official with over 1.5 million RMB, indicating a failure in policy enforcement. The company made financial restatements for fiscal years 2002, 2003, and 2004, related to errors in amortization of vaccine licenses, treatment of license acquisitions, and capitalization of research and development costs. This averages to 0.6 restatements per year over a five-year period (2001-2005).

Kind to Animals

Sinovac Biotech Ltd. conducts animal testing for its vaccine candidates, including mice, rats, and rhesus macaques, as evidenced by preclinical studies for its COVID-19 vaccine and field trials for an animal rabies vaccine.

One COVID-19 vaccine study injected at least 10 rhesus macaques. Mouse and hamster experiments for vaccine development were carried out in accordance with national Danish guidelines and approved by the Danish Animal Experiments Inspectorate. The company's subsidiary, Tangshan Yian, obtained approval from China's Ministry of Agriculture to conduct field trials for an inactivated animal rabies vaccine. The company has not publicly engaged in advocating for animal welfare policy improvement or higher standards.

No War, No Weapons

The provided articles describe Sinovac Biotech Ltd. as a biopharmaceutical company focused on the research, development, manufacturing, and distribution of vaccines for human infectious diseases.

Its activities include providing vaccines to 62 Belt and Road Initiative countries, establishing research projects and production partnerships, and investing in vaccine storage and formulation facilities. The company's Code of Business Conduct and Ethics outlines general ethical conduct, conflict of interest avoidance, and compliance with laws. While some articles discuss US export controls on certain biotechnology components due to dual-use concerns and potential military applications within China's broader biotechnology sector, none of the evidence directly links Sinovac Biotech Ltd. to any arms manufacturing, military contracts, conflict facilitation, or specific investment in dual-use technologies with military applications. Therefore, there is no specific, concrete data to score any of the KPIs under the 'No War, No Weapons' value for Sinovac Biotech Ltd.

Planet-Friendly Business

The company has one project, the Vaccine Quality Research Center, for which an environmental impact assessment (EIA) has been announced, with a public comment period detailed in July 2025.

No other projects subject to full environmental impact assessments are mentioned.

Respect for Cultures & Communities

The provided articles do not contain specific, concrete evidence directly attributable to Sinovac Biotech, Ltd. regarding its own policies, actions, or outcomes related to 'Respect for Cultures & Communities'. While some articles mention government-led vaccination campaigns using Sinovac's vaccines that involve community outreach or language translation (e.g., in Peru, Colombia, Brazil, and Turkey),

these initiatives are attributed to the respective governments or World Bank projects, not to Sinovac's direct engagement or protocols. A general donation of over 8 billion yuan to public health and society by Kexing (a related entity) is mentioned, but this is not specifically directed to cultural heritage organizations, which is the focus of the 'charitable_giving_cultural' KPI. Therefore, no KPIs under this value can be scored based on the available evidence.

Safe & Smart Tech

A leak of personally identifiable information (PII) for 820,000 people in the Dominican Republic was identified.

This leak included COVID vaccination status and records referencing vaccines from Sinovac Biotech.

Zero Waste & Sustainable Products

The company has implemented several waste reduction initiatives, including a management procedure for hazardous waste, rendering harmless and reusing waste embryos as fertilizer, wastewater treatment systems, exhaust treatment systems, general waste management systems, and environmental protection training.

For hazardous waste, a management procedure is in place, waste is sent to third parties for destruction at least monthly, and stored in a securely locked facility. Two service providers are used for chemical and bio-hazardous waste. However, flammable waste (alcohol) was not separated from other waste. The company has had no waste disposal violations in the past three years.